Synopsis of recent research by authors named "Guo Zhu Zheng"
- Guo Zhu Zheng's research primarily focuses on the development of selective estrogen receptor antagonists, particularly targeting mutant estrogen receptor alpha (ERα) to overcome therapy resistance in breast cancer patients.
- Notable findings include the advancement of H3B-6545, a novel covalent ERα antagonist that demonstrates promising preclinical activity against both wild-type and mutant ERα, showcasing its potential for treating metastatic breast cancer.
- Additionally, Zheng's work encompasses diverse areas such as the synthesis of splicing inhibitors and TRPV1 antagonists, bringing insights into mechanisms for pain management and cancer treatment strategies.
